Under the pact, Gilead has extended non-exclusive rights to Strides to manufacture and distribute Under the pact, Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide, both as a single agent product and in combination with other drugs.
Strides Arcolab Limited on Tuesday announced a licensing agreement with Gilead Sciences, Inc for HIV drug Tenofovir Alafenamide (TAF).
Under the pact, Gilead has extended non-exclusive rights for Strides to manufacture and distribute TAF, both as a single agent product and in combination with other drugs, the Strides release said.
The license being granted to Strides extends to 112 countries, which together account for more than 30 million people living with HIV, the release said.
As part of the licensing agreement, pending U.S. Food and Drug administration (US FDA) approval of the Gilead product, Strides will receive a technology transfer from Gilead, enabling Strides to manufacture low-cost versions of TAF for developing countries, the Strides release said.
TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead's Viread® (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile, the release said.
TAF and TAF-based regimens are investigational products in the United States and have not yet been determined safe or efficacious in humans, the release said.
Strides Arcolab stock price
On January 20, 2015, at 12:31 hrs Strides Arcolab was quoting at Rs 938.00, up Rs 11.55, or 1.25 percent. The 52-week high of the share was Rs 999.00 and the 52-week low was Rs 343.80.
The company's trailing 12-month (TTM) EPS was at Rs 645.04 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 1.45. The latest book value of the company is Rs 273.80 per share. At current value, the price-to-book value of the company is 3.43.
Anda sedang membaca artikel tentang
Strides in licensing pact with Gilead Science for HIV drug
Dengan url
https://rokokkanker.blogspot.com/2015/01/strides-in-licensing-pact-with-gilead.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Strides in licensing pact with Gilead Science for HIV drug
namun jangan lupa untuk meletakkan link
Strides in licensing pact with Gilead Science for HIV drug
sebagai sumbernya
0 komentar:
Posting Komentar